2017
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.ccr-16-0150.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaInterleukin-10Lymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm StagingRNA, MessengerV-Set Domain-Containing T-Cell Activation Inhibitor 1ConceptsNon-small cell lung cancerB7-H4PD-L1IDO-1Lung cancerLung carcinomaQuantitative immunofluorescenceIFNγ stimulationElevated PD-L1Major clinicopathologic variablesMultiplexed quantitative immunofluorescenceOptimal clinical trialsT-cell infiltratesCell lung cancerImmune evasion pathwaysHuman lung carcinomaLung adenocarcinoma A549Cancer Genome AtlasClinicopathologic variablesMarker levelsClinical trialsStage ITherapeutic resistanceTCGA datasetA549 cells
2012
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.
Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.Peer-Reviewed Original ResearchSquamous cell carcinomaOP cancerOverall survivalHuman papillomavirusOral cavityAJCC stagePrognostic significanceCell carcinomaStage IFrequency of HPVNeck squamous cell carcinomaCurrent AJCC systemEnd Results registryKaplan-Meier methodEpidemiology of headL. PatientsPrognostic impactAJCC stagingOropharyngeal cancerPrognostic factorsStage IVBSurveillance EpidemiologyAJCC systemPatient populationClinical behavior
2009
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
Gold K, Lee J, Rice D, Tse W, Stewart D, Wistuba I, Herbst R, Lippman S, Hong W, Kim E. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 7566-7566. DOI: 10.1200/jco.2009.27.15_suppl.7566.Peer-Reviewed Original ResearchNon-small cell lung cancerStage ISurgical resectionResectable non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerResponse rateECOG performance status 0Phase II pilot studyAdequate laboratory parametersCurative-intent therapyCycles of chemotherapyDefinitive surgical resectionGrade 3/4 toxicitiesPerformance status 0Radiographic response rateBenefit of chemotherapyComplete pathologic responseEncouraging response ratesCell lung cancerYr of treatmentActive regimenAdjuvant erlotinibCancer ptsEligible pts